x

Posted 30 March, 2022

AVENUE THERAPEUTICS, INC. appointed new CEO

CEO Change detected for ticker Nasdaq:ATXI in a 8-K filed on 30 March, 2022.


  On March 28, 2022, Lucy Lu, M.D. notified Avenue Therapeutics, Inc. (the "Company") that she was resigning from her role as the Company's President and Chief Executive Officer, and from her position as a member of the Company's Board of Directors, effective in each case as of March 31, 2022, in order to pursue an opportunity outside of the Company.  

Don't how to trade CEO change? Read Reasons for CEO Turnover and Effect on Stock Performance.
Overview of AVENUE THERAPEUTICS, INC.
Health Care/Life Sciences • Pharmaceuticals
Avenue Therapeutics, Inc. is a specialty pharmaceutical company, which engages in acquiring, licensing, and commercializing products for use in the intensive care hospital setting. It focuses on the development of intravenous tramadol, a potential alternative that could reduce the use of conventional opioids for patients suffering from acute pain. The company was founded on February 9, 2015 and is headquartered in Bay Harbor Islands, FL.
Market Cap
$2.05M
View Company Details
AVENUE THERAPEUTICS, INC. by TradingView
Relevant filing section
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.


On March 28, 2022, Lucy Lu, M.D. notified Avenue Therapeutics, Inc. (the "Company") that she was resigning from her role as the Company's President and Chief Executive Officer, and from her position as a member of the Company's Board of Directors, effective in each case as of March 31, 2022, in order to pursue an opportunity outside of the Company. Dr. Lu did not resign from these positions as a result of any disagreement with the Company on any matter relating to the Company's operations, financial reporting or controls. The Company has entered into a consulting arrangement with Dr. Lu effective March 31, 2022.


David Jin, who was previously serving as the Company's Chief Operating Officer, will begin acting as the Company's interim principal executive officer as of March 31, 2022. 


The Company continues to evaluate potential strategic transaction options for the Company.